Abstract 1901P
Background
Here, we describe the potential of measuring dynamic changes occurring in peripheral blood as indicators of response to NIVO in mRCC pts.
Methods
After failure to antiangiogenics, mRCC pts (n=60) received NIVO within the I-RENE trial (NCT04891055). Blood samples were collected during NIVO at baseline, 2, 4, 12 weeks (wks) and at PD. Therapy induced dynamic changes were evaluated in PBMCs and plasma, by high resolution flow cytometry (n=144 lymphoid and myeloid cell subsets) and multiplex analysis, respectively. A panel of very good (n=17, R) and very poor (n=16, NR) responders were selected for correlations. Tumor transcriptomics and immune infiltrate assessment were performed on baseline biopsy to gain insight into the immunomodulation occurring at tumor site.
Results
Dynamic changes were detected in multiple PBMC subsets and plasma cyto/chemokines since 2 wks from NIVO and at subsequent time points in all pts. However, R pts showed at 2 wks a statistically significant decrease of monocytic MDSCs (M-MDSC, CD14+HLA-DRneg) cells, followed at 4 wks by a boost of CD8+ and central memory T cells, and reduction of CD38+ T cells. At 12 wks CD14+HLA-DRneg MDSCs reached the lowest peripheral blood level without further changes in the lymphoid cell subsets. At opposite, NR pts showed a progressive increase of M-MDSCs and inflammatory/immunosuppressive monocytes (CD14+PD-L1+), associated at 12 wks with a significant upregulation of senescent (KLRG1+CD28-CD57+) CD8+ T cells and CD38+ T cells. Nivo induced a decrease of plasma IL-8, Pentraxin 3, PCSIK9 and miR-125b, and an increase of VEGFR2, all of which were associated with good response at 12 wks. Integration of PBIP with tumor tissue results will pair systemic immunomodulations with tumor microenvironment.
Conclusions
Specific kinetics of immunosuppressive myeloid cell subsets versus memory/effector T cells early during NIVO associate with outcome. Combining dynamic peripheral blood variables with clinical information may give rise to novel biomarkers for tailored therapeutic decision-making in mRCC pts.
Clinical trial identification
NCT04891055.
Editorial acknowledgement
Legal entity responsible for the study
Fondazione IRCCS Istituto Nazionale Tumori di Milano – Italy.
Funding
Italian Ministry of Health (RF-2016_02363001) AIRC IG 25078.
Disclosure
E. Verzoni: Financial Interests, Personal, Advisory Board: Msd, Janssen, AstraZeneca; Financial Interests, Personal, Invited Speaker: BMS, Astellas, Ipsen, Pfizer; Non-Financial Interests, Principal Investigator: MSD, Ipsen, Astellas, Janssen, Lilly, Pfizer. G. Procopio: Financial Interests, Personal, Advisory Board, consultant fees: Astellas, AstraZeneca, Bayer, BMS, Janssen, Ipsen, Merck, MSD, Novartis, Pfizer; Financial Interests, Institutional, Research Grant, research funding for no profit clinical trial: Ipsen. P.A. Zucali: Financial Interests, Institutional, Local PI: Merck, Bayer, Pfizer, BMS Int. Corp. Belgium Branch. G. fornarini: Financial Interests, Personal, Advisory Board: Amgen, Astellas, BMS, Janssen, Eisai, Ipsen, Pfizer, Bayer; Financial Interests, Personal, Other, ESMO meeting - travel accommodation: Ipsen. S. Buti: Financial Interests, Personal, Advisory Board: BMS, Pfizer, MSD, MSD, Ipsen, AstraZeneca, Pierre-Fabre, Novartis; Financial Interests, Personal, Invited Speaker: BMS, MSD, Ipsen, AstraZeneca, Novartis; Financial Interests, Institutional, Local PI: BMS, Ipsen, AstraZeneca; Financial Interests, Institutional, Coordinating PI: BMS, MSD; Financial Interests, Institutional, Research Grant: Novartis; Non-Financial Interests, Other, Member of panel for kidney cancer guidelines: AIOM (Italian Association of Medical Oncology); Non-Financial Interests, Other, member and coordinator of the “Rare Tumors” group: Meet-URO group (Italian Network For Research In Urologic-Oncology). All other authors have declared no conflicts of interest.
Resources from the same session
1726P - Optimizing oncology drug spending in a cancer centre in Ireland
Presenter: Ruth Kieran
Session: Poster session 23
1727P - Barriers and facilitators of physician involvement in clinical oncology database management in Ukraine
Presenter: Inesa Huivaniuk
Session: Poster session 23
1728P - Implementation of a comprehensive oncology unit: Needs detected in cancer survivors during follow-up
Presenter: Francisco J Jimenez-ruiz
Session: Poster session 23
1729P - Targeted interventions in registration and reporting of multidisciplinary team meetings (MDT) in oncology help to improve tumor board decisions
Presenter: Lars Galonska
Session: Poster session 23
1730P - Dealing with digital paralysis: Surviving a cyberattack in a cancer centre
Presenter: Rachel J. Keogh
Session: Poster session 23
1731P - Providing access to anticancer drugs within an armed conflict: The experience of Mission Kharkiv (MK) and Medecins Sans Frontieres (MSF) in Ukraine
Presenter: Stanislav Polozov
Session: Poster session 23
1732P - War and the fragility of anticancer drug supply networks in Ukraine
Presenter: Olha Kostenchak-Svystak
Session: Poster session 23
1733P - Two wars at time: Fight against cancer during war time - experience of Ukraine
Presenter: Veronika Patsko
Session: Poster session 23
1734P - Early impact of a personalized lung cancer interception program for heavy smokers
Presenter: Pamela Abdayem
Session: Poster session 23
1735P - Impact of revised US Preventive Services Task Force (USPSTF) 2021 lung cancer screening guideline on long-term cancer survivors in the United States
Presenter: Qian Wang
Session: Poster session 23